Eric Stewart

Eric Stewart is a Senior Managing Director at Leerink Partners leading the firm’s European M&A practice. He provides strategic and financial advice to clients across the pharmaceutical, biotech, medical technology, life science tools, and diagnostics sectors.

Eric joined the Firm in 2025 from Lazard, where he was a Managing Director. While at Lazard, he recently advised Mallinckrodt on its $6.7bn merger with Endo, Calliditas Therapeutics on its $1.1bn sale to Asahi Kasei, Galderma on its $17bn IPO, Abcam on its $5.7bn sale to Danaher, Calypso on its up to $425mm sale to Novartis, Johnson & Johnson on its spin-off of Kenvue, Fresenius on its $900m joint venture with mAbxience, Syndesi on its up to $1.0bn sale to AbbVie, and UCB on its $1.9bn acquisition of Zogenix. Prior to his 15+ year career in investment banking, Eric began his career at Stryker Corporation.

Eric holds a B.A. in Economics from the University of Michigan.